Vol 71, No 5 (2020)
Clinical vignette
Published online: 2020-08-27

open access

Page views 1074
Article views/downloads 692
Get Citation

Connect on Social Media

Connect on Social Media

Regular chromogranin A monitoring facilitated the early detection of a gastrointestinal neuroendocrine tumour in a patient with type 1 diabetes

Zoltan Herold1, Andrea Uhlyarik1, Magdolna Herold1, Peter Nagy2, Gergely Denes Huszty3, Klara Rosta4, Marton Doleschall5, Aniko Somogyi1
Pubmed: 32856287
Endokrynol Pol 2020;71(5):483-484.

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Wang R, Zheng-Pywell R, Chen HA, et al. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019; 12: 1179551419884058.
  2. Herold Z, Doleschall M, Kovesdi A, et al. Chromogranin A and its role in the pathogenesis of diabetes mellitus. Endokrynol Pol. 2018; 69(5): 598–610.
  3. Herold Z, Herold M, Nagy P, et al. Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis. J Diabetes Investig. 2019 [Epub ahead of print].
  4. De Block CEM, Colpin G, Thielemans K, et al. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. Diabetes Care. 2004; 27(6): 1387–1393.
  5. Bizzaro N, Antico A, Villalta D. Autoimmunity and Gastric Cancer. Int J Mol Sci. 2018; 19(2).